Who is the CEO of Anthem Biosciences Limited?
- Answer Field
-
Dr. Ajay Bhardwaj is the CEO and Managing Director of Anthem Biosciences Limited.
BAJAJ BROKING
Anthem Biosciences Limited, incorporated in 2006, operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) with integrated operations across drug discovery, development, and manufacturing. The company caters to a wide range of customers globally, from emerging biotech firms to established pharmaceutical companies. Its offerings include fermentation-based active pharmaceutical ingredients such as peptides, enzymes, probiotics, vitamin analogues, and biosimilars. As of September 30, 2024, the company was involved in 196 ongoing projects, which include discovery, early and late-phase development, and commercial manufacturing.
The company’s CRDMO platform is structured around five key modalities—RNAi, ADC, peptides, lipids, and oligonucleotides—and four manufacturing capabilities that include fermentation, flow chemistry, custom synthesis, and biotransformation. Anthem serves customers in over 44 countries and holds intellectual property in India and abroad, with multiple patent applications pending. With a team of 600 professionals from varied scientific backgrounds, the company derives revenue from CRDMO services and specialty ingredients production.
For more details, visit the Anthem Biosciences IPO page.
Details | Information |
IPO Date | July 14, 2025 to July 16, 2025 |
Issue Size | 5,95,61,404 shares (aggregating up to ₹3,395.00 Cr) |
Price Band | ₹540 to ₹570 per share |
Lot Size | 26 shares |
Listing At | BSE NSE |
Carry out the Offer for Sale of up to [?] Equity Shares of face value of ? 2 each by the Selling Shareholders aggregating up to ? 33,950.00 million
Achieve the benefits of listing the Equity Shares on the Stock Exchanges
Event | Date |
---|---|
IPO Open Date | Mon, Jul 14, 2025 |
IPO Close Date | Wed, Jul 16, 2025 |
Tentative Allotment | Thu, Jul 17, 2025 |
Initiation of Refunds | Fri, Jul 18, 2025 |
Credit of Shares to Demat | Fri, Jul 18, 2025 |
Tentative Listing Date | Mon, Jul 21, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on July 16, 2025 |
₹540 to ₹570 per share
Application | Lots | Shares | Amount |
Retail (Min) | 1 | 26 | ₹14,820 |
Retail (Max) | 13 | 338 | ₹1,92,660 |
S-HNI (Min) | 14 | 364 | ₹2,07,480 |
S-HNI (Max) | 67 | 1,742 | ₹9,92,940 |
B-HNI (Min) | 68 | 1,768 | ₹10,07,760 |
Log in to Your Trading Account
Access your trading account through your broker’s platform.
Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Select Anthem Biosciences IPO
Find "Anthem Biosciences IPO" and click on the ‘Apply’ button.
Enter Application Details
Specify the number of lots (minimum lot size: 26 shares) and the bid price within the range of ₹540 to ₹570 per share.
Provide Your UPI ID
Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.
Review and Submit
Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on July 16, 2025, to complete your application process.
Total Assets: Grew from ₹2,014.46 crore in FY23 to ₹2,807.58 crore as of March 2025.
Revenue: Reached ₹1,930.29 crore in FY25.
Profit After Tax (PAT): Stood at ₹451.26 crore for March 2025.
Net Worth: Recorded at ₹2,409.86 crore in FY25.
Reserves and Surplus: Recorded at ₹2,298.05 crore (March 2025), growing steadily over the years.
EBITDA: Stood at ₹683.78 crore in March 2025.
The company has experienced consistent growth in its total assets over recent financial years.
Revenue generation has shown an upward trend, indicating increased business activity and market presence.
Profitability has improved, reflecting operational efficiency and cost management.
The company’s net worth has strengthened, supported by retained earnings and a solid capital base.
Reserves and surplus have grown steadily, suggesting effective financial planning and reinvestment.
Operating performance remains stable, with earnings before interest, taxes, depreciation, and amortisation showing healthy levels.
The company’s business is exposed to regulatory changes and compliance requirements across different international markets, which may affect operations.
Success depends on ongoing R&D efforts, and a lower-than-expected transition of molecules from development to commercialisation could impact future revenue streams.
Anthem Biosciences operates across multiple therapeutic platforms and offers end-to-end CRDMO services, positioning it to meet diverse client needs globally.
A growing international client base, pending patent applications, and specialised manufacturing capabilities support expansion in both CRDMO and specialty ingredient segments.
KPI | Values |
ROE | 20.82% |
ROCE | 26.88% |
Debt/Equity | 0.05 |
RoNW | 20.82% |
PAT Margin | 23.38% |
EBITDA Margin | 36.81% |
Price to Book Value | 13.23 |
Registrar | Lead Manager(s) |
---|---|
Kfin Technologies Limited | Jm Financial Limited |
Anthem Biosciences Ltd.
No. 49, F1 & F2, Canara Bank Road
Bommasandra Industrial Area, Phase 1,
Bommasandra,
Bengaluru, Karnataka, 560099
Phone: +91 080 6672 400
Email: investors.abl@anthembio.com
Website: https://www.anthembio.com/
Anthem Biosciences Limited is engaged in offering contract research, development, and manufacturing services to a varied clientele across global markets. Its operations span multiple modalities and manufacturing technologies, supported by a team of professionals from different scientific fields. The company’s revenue sources include CRDMO services and specialty ingredients, with activities spread across discovery, development, and commercial manufacturing stages.
The upcoming IPO is structured as an Offer for Sale, with the objective of achieving a stock exchange listing. The company has shown growth in operational and financial metrics over recent years. Interested participants may consider the timeline, application process, and price band details before proceeding with the IPO application.
Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Anthem Biosciences IPO.
Share this article:
No result found
Dr. Ajay Bhardwaj is the CEO and Managing Director of Anthem Biosciences Limited.
The IPO is scheduled to open on July 14, 2025, and will close on July 16, 2025.
Anthem Biosciences operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), offering integrated services across drug discovery, development, and manufacturing. It serves a global customer base and is involved in multiple therapeutic platforms. The business model relies on R&D, commercial manufacturing, and specialty ingredients, supported by intellectual property and scientific expertise. Sustainability depends on regulatory compliance, ongoing innovation, and customer retention.
The IPO comprises 5,95,61,404 equity shares, aggregating up to ₹3,395 crore, via an Offer for Sale.
‘Pre-apply’ refers to placing a bid for the IPO before the official subscription window opens. This facility is usually available through online trading platforms and ensures that the order is queued once the IPO opens.
After submitting the application and approving the UPI mandate, you will receive a confirmation from your broker or app. The status can also be checked under the IPO application section of your Demat account or UPI app.
The minimum lot size is 26 shares. Retail investors must apply for at least one lot.
The tentative allotment date is July 17, 2025.
The registrar for the IPO is Kfin Technologies Limited.
As of publicly available data, there are no reported governance concerns or red flags in the leadership or board structure of Anthem Biosciences Limited.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading